Stocktoria
Alkermes plc. ALKS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1991-07-16
Alkermes plc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.5B | $1.6B | $1.7B | $1.1B | $1.2B |
| R&D expense | $324.0M | $245.3M | $270.8M | $272.7M | $290.9M |
| SG&A expense | $701.5M | $645.2M | $689.8M | $590.8M | $549.6M |
| Operating income | $254.0M | $420.6M | $414.1M | -$6.1M | $97.7M |
| Interest expense | — | — | $23.0M | $13.0M | $11.2M |
| Income tax | $49.8M | $71.6M | -$97.6M | $2.0M | $11.3M |
| Net income | $241.7M | $367.1M | $355.8M | -$158.3M | -$48.2M |
| EPS (diluted) | $1.43 | $2.17 | $2.10 | $-0.97 | $-0.29 |
| Operating cash flow | $520.8M | $439.1M | $401.4M | $21.0M | $101.7M |
| Free cash flow | $480.3M | $405.6M | $353.3M | -$17.2M | $73.7M |
| Cash & equivalents | $388.6M | $291.1M | $457.5M | $292.5M | $337.5M |
| Inventory | $196.6M | $182.9M | $186.4M | $181.4M | $150.3M |
| Total assets | $2.5B | $2.1B | $2.1B | $2.0B | $2.0B |
| Total liabilities | $667.7M | $590.6M | $933.5M | $920.2M | $911.9M |
| Shareholders' equity | $1.8B | $1.5B | $1.2B | $1.0B | $1.1B |
Source: SEC EDGAR filings · CIK 0001520262 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.